W. R. Berkley
WRB
$75.42
+1.96%
W.R. Berkley Corporation is an insurance holding company whose subsidiaries primarily underwrite commercial casualty insurance, specializing in niche excess and surplus lines, workers' compensation, self-insurance consulting, reinsurance, and regional commercial lines for small and midsize businesses. It is a disciplined, decentralized specialty underwriter that has built a reputation as one of the premier excess and surplus (E&S) franchises in the U.S., distinguished by its granular underwriting culture and a portfolio of autonomous operating units rather than a single monolithic carrier. The current investor debate centers on whether the multi-year hard-market cycle in commercial P&C is cresting: headline revenue growth has been dramatic, but much of the recent top-line surge reflects a sharp jump in ceded and assumed premium flows rather than organic underwriting expansion, while the bottom line has been pressured by a rising expense base and a higher tax rate. Analysts are split on the durability of margins as rate increases decelerate, and the stock's muted one-year relative performance against the broader market reflects that skepticism even as shares have recovered toward the upper end of their range.…
WRB
W. R. Berkley
$75.42
Related headlines
WRB 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on W. R. Berkley's 12-month outlook, with a consensus price target around $69.06 and implied upside of -8.4% versus the current price.
Average Target
$69.06
0 analysts
Implied Upside
-8.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$51 - $83
Analyst target range
Seventeen analysts cover WRB with a consensus recommendation of "hold" (mean rating 3.39 on a 1-to-5 scale where higher is more bearish), and the average target price of $69.06 implies roughly 8.4% downside from the current $75.42 — a notable signal that the stock has run past the Street's fair-value estimate. The distribution skews cautious: recent actions include B of A Securities downgrading to Underperform from Neutral (July 16), Wells Fargo and Evercore ISI maintaining Underweight/Underperform stances, and Mizuho, UBS, and Cantor Fitzgerald staying Neutral, with Truist the lone Buy in the recent tape. The consensus is therefore neutral-to-bearish, and the fact that the stock trades above the average target suggests either the market is ahead of analyst revisions or the shares are technically extended relative to fundamental expectations.\n\nThe target range is wide — $51.00 low to $83.00 high — a spread of roughly 63% around the average, which signals genuine disagreement about the margin trajectory rather than a simple timing mismatch. The $83.00 high target implies roughly 10% upside and would require multiple expansion or a stabilization of underwriting margins plus continued capital returns; the $51.00 low target implies about 32% downside and prices in meaningful margin compression, adverse reserve development, or a cyclical softening in commercial P&C rates. The wide dispersion, combined with the recent cluster of Neutral-to-Underperform ratings and the absence of upgrades, points to low conviction and elevated uncertainty — investors should treat the average target as a soft ceiling rather than a floor, and watch for estimate revisions around the next earnings print as the key catalyst for closing the gap between price and consensus.
Drowning in data?
Find the real signal!
Bulls vs Bears: WRB Investment Factors
The bear case currently carries slightly stronger evidence: the stock trades 8.4% above the consensus target with a 'hold' rating, margins have compressed sharply (net margin 6.62% in Q2 2026 versus 13.97% in Q1), and the PEG of 7.63 exposes the multiple to de-rating. The bull case rests on genuine quality — 18.34% ROE, 0.29 debt-to-equity, $3.50 billion TTM free cash flow, and a 0.271 beta — plus accelerating near-term momentum that has beaten the S&P 500 by 6.60 points in a month. The single most important tension is whether the Q2 revenue surge is a durable reinsurance/accounting effect or a one-off distortion masking underlying premium deceleration; how that resolves will determine whether margins stabilize or the stock de-rates toward its 12-13x historical PE. Until the next earnings print clarifies revenue quality and expense trajectory, the risk/reward at $75.42 is balanced-to-unfavorable.
Bullish
- Near-term momentum decisively outperforming: WRB is up 7.82% over the past month and 12.85% over six months versus a 2.40% one-year gain, outperforming the S&P 500 by 6.60 and 5.37 percentage points over those windows respectively. The 1.96% single-session jump to $75.42 on the latest print confirms buyers control the tape, and the stock sits at roughly 87.5% of its 52-week range.
- Fortress balance sheet with strong cash generation: Debt-to-equity is just 0.29 with total debt to capitalization of 21.8% and interest coverage near 18-19x, while trailing free cash flow is $3.50 billion ($811.9 million in Q2 2026 alone). Operating cash flow of $800.0 million comfortably funds $111.5 million of buybacks plus the dividend, meaning growth is internally financed.
- Healthy returns and shareholder yield: ROE of 18.34% and a trailing net margin of 12.10% are respectable for a P&C underwriter, and the 2.52% dividend yield with a conservative 39.4% payout ratio leaves room for continued buybacks (share count drifted from 400.4 million diluted in Q2 2025 to 391.8 million in Q2 2026).
- Low beta defensive profile: A beta of 0.271 means the stock moves at roughly 27% of the market's amplitude, consistent with a low-duration specialty underwriter. For risk-budgeted portfolios this supports larger position sizing and provides diversification against high-beta growth exposure.
Bearish
- Price above consensus target: The $75.42 price sits roughly 8.4% above the $69.06 average analyst target, and the consensus rating is 'hold' at 3.39 on a 1-to-5 scale. Recent actions skew negative — B of A downgraded to Underperform on July 16, with Wells Fargo and Evercore at Underweight/Underperform and only Truist at Buy.
- Severe margin compression: Q2 2026 net margin fell to 6.62% from 13.97% in Q1 2026 and 13.56% in Q3 2025, while operating margin dropped to 8.42% from 16.70% and 17.71% respectively. The effective tax rate also rose to 21.4% from 16.3%, compounding the earnings pressure.
- Revenue growth quality is questionable: The 86.1% year-over-year revenue jump to $6.83 billion from $3.67 billion is far out of line with the underlying premium trend and appears driven by ceded/assumed premium and investment flows rather than organic underwriting. Consensus forward revenue of ~$16.46 billion implies normalization, not continuation of the Q2 run-rate.
- PEG of 7.63 signals growth mismatch: A PEG ratio of 7.63 is elevated and shows the 15.65x multiple is not supported by high expected growth, while price-to-cash-flow of 7.64x is rich versus the sector's mid-to-high single-digit range. If margins keep compressing, the multiple could de-rate toward the 12-13x historical average seen in 2022-2023.
WRB Technical Analysis
WRB is in a recovery uptrend that has reclaimed most of its prior ground, with the stock up 2.40% over the trailing year and trading at roughly 87.5% of its 52-week range (current price $75.42 versus a 52-week low of $62.87 and high of $78.96). That positioning near the upper quartile of the range signals momentum is intact but leaves limited headroom before the stock tests its ceiling, and the 19.02% maximum drawdown over the period underscores that this has been a choppy, two-steps-forward climb rather than a clean trend. The 52-week high of $78.96 sits only about 4.7% above the current price, making the resistance zone the immediate battleground for bulls.\n\nShort-term momentum is clearly accelerating and has decisively outpaced the longer-term trend: the stock is up 7.82% over the past month and 5.32% over three months, versus a 2.40% one-year gain, and it has gained 12.85% over six months. This positive divergence — a strong recent thrust against a flat annual trend — suggests the stock is emerging from a consolidation phase rather than reversing a downtrend, and the 1.96% single-day jump on the latest session (from a previous close of $73.97 to $75.42) confirms buyers are in control near-term. Relative strength tells the same story: WRB has outperformed the S&P 500 by 6.60 percentage points over the past month and 5.37 points over six months, though it still lags the index by 13.13 points over the full year, a gap that recent momentum is beginning to close.\n\nKey technical levels are well defined: support rests at the 52-week low of $62.87, roughly 16.6% below the current price, while resistance at the $78.96 high is the level to watch — a clean breakout above it would confirm a new leg higher and likely draw momentum buyers, whereas a rejection there could set up a double-top and a retest of the $70 area. A breakdown below $62.87 would be technically damaging and signal a broader trend failure. Volatility is unusually low for an equity: the beta of 0.271 implies the stock moves at roughly 27% of the market's amplitude, consistent with the defensive, low-duration characteristics of a P&C underwriter, which supports larger position sizing for risk-budgeted portfolios but also means the stock will likely lag in strong risk-on rallies — as the 13.13-point one-year relative underperformance versus SPY demonstrates.
Beta
0.27
0.27x market volatility
Max Drawdown
-19.0%
Largest decline past year
52-Week Range
$63-$79
Price range past year
Annual Return
+2.4%
Cumulative gain past year
| Period | WRB Return | S&P 500 |
|---|---|---|
| 1m | +7.8% | +0.2% |
| 3m | +5.3% | +2.9% |
| 6m | +12.9% | +8.4% |
| 1y | +2.4% | +14.9% |
| ytd | +8.7% | +11.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
WRB Fundamental Analysis
The revenue trajectory is growing but the quality of that growth is the central question. Most recent quarterly revenue (Q2 2026) came in at $6.83 billion, up 86.1% year-over-year from $3.67 billion in Q2 2025 — an extraordinary jump that is far out of line with the underlying premium trend and appears driven by a surge in ceded/assumed premium and investment-related flows rather than organic underwriting. Sequentially, revenue rose from $3.69 billion in Q1 2026 and $3.72 billion in Q4 2025, so the step-change is concentrated in the latest quarter and warrants scrutiny; the reinsurance-global segment contributed $432.1 million, a modest slice of the total. For the investment case, the key is whether this is a one-off accounting or reinsurance effect or the start of a durable acceleration — the consensus revenue estimate of roughly $16.46 billion for the forward period implies normalization rather than continuation of the Q2 run-rate.\n\nProfitability remains solid but is compressing at the margin. Q2 2026 net income was $452.3 million with a net margin of 6.62%, down sharply from $515.2 million and a 13.97% net margin in Q1 2026 and from $511.0 million (13.56% margin) in Q3 2025, while the reported gross margin of 71.3% is inflated by the revenue-mix distortion and is not comparable to the 18–25% gross margins reported in prior quarters. Operating margin of 8.42% in Q2 2026 versus 16.70% in Q1 2026 and 17.71% in Q3 2025 confirms real expense pressure, and the effective tax rate rose to 21.4% from 16.3% the prior quarter. The trailing net margin of 12.10% and operating margin of 15.87% are respectable for a P&C insurer, but the direction of travel — margin compression on a rising expense base — is the number that matters for the thesis.\n\nThe balance sheet is conservatively managed and cash generation is robust. Debt-to-equity stands at 0.29, total debt to capitalization is 21.8%, and interest coverage of roughly 18–19x is comfortable; the current ratio of 1.39 reflects the liquid, investment-heavy asset base typical of insurers. Free cash flow is strong at $3.50 billion TTM, with quarterly FCF of $811.9 million in Q2 2026 and $667.9 million in Q1 2026, and operating cash flow of $800.0 million in the latest quarter comfortably funds the $111.5 million of buybacks and the dividend (yield 2.52%, payout ratio 39.4%). ROE of 18.34% is healthy, though the quarterly ROA readings of roughly 1.0–1.2% reflect the leverage inherent in the insurance model; overall, WRB funds growth internally with minimal external financing dependence, a meaningful quality marker.
Quarterly Revenue
$6.8B
2026-06
Revenue YoY Growth
+86.1%
YoY Comparison
Gross Margin
71.3%
Latest Quarter
Free Cash Flow
$3.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is WRB Overvalued?
Because W.R. Berkley is solidly profitable (Q2 2026 net income of $452.3 million), the PE ratio is the appropriate primary metric. The stock trades at 15.65x trailing earnings and 15.40x forward earnings — a narrow gap that implies the market expects only modest earnings growth, consistent with the consensus EPS estimate of $5.14 versus the current run-rate. The PEG ratio of 7.63 is elevated and signals that the current multiple is not being supported by high expected growth, which is the key valuation tension for the name.\n\nOn a peer basis, the 15.65x trailing PE and 2.87x price-to-book are moderate for a specialty P&C underwriter, though the 1.89x price-to-sales and 11.85x EV/EBITDA sit at the fuller end of the insurance range; the 7.64x price-to-cash-flow is rich relative to the sector's typical mid-single-digit to high-single-digit range. The forward PE of 15.40x versus trailing 15.65x offers essentially no multiple compression, meaning the market is not pricing in meaningful earnings acceleration — a discount relative to growth-oriented financials but a premium to the cheapest value insurers. The 2.52% dividend yield and 39.4% payout ratio provide a modest income cushion that supports the multiple.\n\nAgainst its own history, the current 15.65x PE sits in the middle-to-upper portion of its multi-year band: the stock traded at 10.1x in Q4 2024, 12.0x in Q4 2023, and 13.1x in Q4 2022, so today's multiple represents a meaningful re-rating from the low-teens. Price-to-book of 2.87x is likewise above the 2.57–2.68x readings of 2023–2024 but below the 3.1x peaks of mid-2025. The read-through is that the market is pricing in stable-to-improving underwriting conditions; if margins continue to compress, there is room for the multiple to de-rate back toward the 12–13x historical average, making the current valuation more dependent on execution than on cheapness.
PE
15.7x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 10x~18x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on margin erosion and revenue quality. Q2 2026 net margin collapsed to 6.62% from 13.97% in Q1 2026, operating margin fell to 8.42% from 16.70%, and the effective tax rate climbed to 21.4% from 16.3%, showing the expense base is rising faster than underlying premium. The 86.1% revenue jump to $6.83 billion is heavily distorted by ceded/assumed premium flows, and the reported 71.3% gross margin is not comparable to the 18-25% readings of prior quarters, meaning investors cannot rely on headline growth as a proxy for underwriting expansion. Positively, leverage is modest at 0.29 debt-to-equity with 18-19x interest coverage and $3.50 billion TTM free cash flow, so the risk is to earnings quality rather than solvency.
Market and competitive risks are dominated by valuation compression and cyclical softening. At 15.65x trailing earnings and 2.87x book, WRB has re-rated from 10.1x in Q4 2024 and 12.0x in Q4 2023; a return to the 12-13x historical average would imply roughly 17-23% multiple-driven downside even with flat earnings. The PEG of 7.63 and 7.64x price-to-cash-flow sit at the rich end of the insurance range, and the stock trades 8.4% above the $69.06 consensus target with a 'hold' rating and a cluster of Underperform/Underweight calls (B of A, Wells Fargo, Evercore). A beta of 0.271 limits macro-driven drawdown but also means WRB will lag in risk-on rallies, as the 13.13-point one-year underperformance versus SPY demonstrates; sector rotation out of defensives would compound this.
In a worst-case scenario, commercial P&C rates soften faster than expected, the Q2 revenue surge proves non-recurring, and adverse reserve development forces margin guidance lower — triggering estimate cuts and a de-rating toward 12x earnings. That combination would take the stock toward the $51.00 analyst low target, roughly 32% below the current $75.42, with the 52-week low of $62.87 (about 16.6% downside) as an intermediate support that would likely break in a genuine cyclical downturn. The 19.02% max drawdown over the past year shows how quickly sentiment can reverse in this name. Realistically, an investor could lose 17-32% from current levels in the adverse case, with the low end requiring both multiple compression and earnings disappointment.
